deepull appoints Kimberle Chapin, MD, as Chief Medical Officer and Wade Stevenson as Chief Marketing and Sales Officer
18 April 2024 - 7:00AM
deepull appoints Kimberle Chapin, MD, as
Chief Medical Officer and Wade Stevenson as Chief Marketing and
Sales Officer
- Kimberle Chapin brings significant
expertise in microbiology and infectious diseases
- Wade Stevenson is a senior
marketing leader specialising in infectious diseases and molecular
diagnostics
Barcelona, Spain – 18 April 2024
– deepull, a medical diagnostics company developing
culture-free diagnostic solutions for rapid pathogen identification
for sepsis and other acute infections, today announces the
appointments of Dr Kimberle Chapin as Chief Medical Officer and
Wade Stevenson as Chief Marketing and Sales Officer.
Jordi Carrera, Chief Executive Officer
and Co-Founder of deepull, said: “Kim and Wade are joining
at an important time for the business as it progresses its
automated sepsis diagnostic test. Their combined expertise will be
pivotal in the development of deepull’s direct-from-blood, rapid
diagnostics system.”
Kimberle Chapin is a Professor of Medicine and
Pathology and Laboratory Medicine at the Warren Alpert School of
Medicine at Brown University. She is highly experienced in the
clinical management of laboratory diagnostics, with a focus on
infectious diseases. Previously, Kimberle worked as Chief Medical
Officer at Cepheid and for 17 years she was the Director of
Clinical Microbiology and Molecular Diagnostics for Infectious
Diseases for Lifespan Academic Medical Center. Kimberle received
her MD and MSc. in Molecular Genetics and Microbiology from the
University of Massachusetts, and her B.S. in Biology from Boston
College.
Wade is a seasoned commercial leader and
marketing executive with more than 25 years’ experience in
infectious diseases, molecular diagnostics, and pharmaceuticals. He
spent 18 years at the global diagnostics company BioFire
Diagnostics, latterly bioMérieux, in a variety of roles. As VP
North America Clinical Marketing he was responsible for the global
commercial success of the BioFire franchise. Previous roles include
Vice President Marketing of Roche’s US molecular laboratory, where
he oversaw a broad portfolio of molecular in-vitro diagnostic
assays and instruments as well as next-generation sequencing
products. Wade received his MBA from the University of North
Carolina Kenan-Flagler Business School, and his B.S. in Zoology
from Brigham Young University.
“deepull’s innovative approach to rapid pathogen
identification has the potential to provide a marked improvement
over standard of care testing for patients with sepsis,”
said Dr. Kimberle Chapin, new Chief Medical Officer of
deepull. “I am looking forward to sharing my experience
from the laboratory and clinical practice to help deliver improved
patient outcomes through early detection.”
“I have been working in the diagnostics space
for many years and believe deepull’s approach could transform
hospital laboratory testing and support compliance with sepsis
guidelines. The next few months will be important as we drive
forward with the development of this rapid diagnostics solution and
build out our commercial strategy,” commented Wade
Stevenson, Chief Marketing and Sales Officer at
deepull.
-Ends-
Notes to editors
About deepull
deepull is a medical diagnostics company
developing culture-free diagnostic solutions for sepsis and acute
infections. Founded in 2020 in Barcelona by the founders of STAT-Dx
(sold to QIAGEN in 2018), deepull has assembled a team of
world-class experts to create rapid and accessible diagnostic
solutions.
deepull is developing a 1 hour,
direct-from-blood PCR test targeting 95% of sepsis-causing
pathogens. The test will extract total microbial DNA from 8mL of
whole blood and include 50 reportable results. The test runs on the
deepull UllCORE instrument; a benchtop system with sample-to-result
automation being designed to meet the needs of any hospital
clinical laboratory.
For more information, please contact:
deepull
Agustina
Boullaude Email:
aboullaude@deepull.com
ICR Consilium
Amber Fennell / Lucy Featherstone
Email: deepull@consilium-comms.com